Achieving “Sustainability That Only Our Company Can Deliver”
First written in FY2023. 2 of 3 entries say "Advanced", first in FY2024. Latest entry: FY2026.
The whole theme swung hardest in 2019: 1 of 9 companies on the "Worse" side.
52 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「By actively pursuing the development of treatments and the creation of new business models for ultra-rare diseases affecting extremely few patients, the Company aims to realize a society that leaves no one behind, not only in Japan but throughout the world, for patients waiting for treatments.」
In the rare-disease area of sustainability, the Company identified the development of treatments for ultra-rare diseases, including Ultra Rare diseases, and the creation of new business models as priority initiatives. - FY2024AdvancedAnnual report
「The Company is advancing initiatives in the following priority areas: "Rare Diseases," "Environment," "Society" and "Corporate Governance."」
The Company organized its priority sustainability areas as RD, E, S and G, and systematically disclosed its materiality, key indicators, results and initiatives. - FY2023First statedAnnual report
「To realize this vision, the Company will pursue "sustainability that only the Company can deliver" through the following 3 initiatives: • Realizing sustainable healthcare • Growth of people and organizations (promoting human capital management) • Addressing social issues (environmental conservation initiatives)」
The Company organized its sustainability initiatives into 3 areas: sustainable healthcare, growth of people and organizations, and social issues and environmental conservation. In July 2022, it established the Sustainability Advisory Committee, Sustainability Committee and Environmental Committee.